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Abstract
Background: This study tested the ability of a characterized extract of Polygonum cuspidatum
(PCE) to inhibit mouse ear inflammation in response to topical application of 12-O-
tetradecanoylphorbol-13-acetate (TPA).
Methods: A 50% (wt:vol) ethanolic solution of commercial 200:1 PCE was applied to both ears of
female Swiss mice (n = 8) at 0.075, 0.15, 0.3, 1.25 and 2.5 mg/ear 30 min after TPA administration
(2 µg/ear). For comparison, 3 other groups were treated with TPA and either 1) the vehicle (50%
ethanol) alone, 2) indomethacin (0.5 mg/ear), or 3) trans-resveratrol (0.62 mg/ear). Ear thickness
was measured before TPA and at 4 and 24 h post-TPA administration to assess ear edema. Ear
punch biopsies were collected at 24 h and weighed as a second index of edema. Myeloperoxidase
activity was measured in each ear punch biopsy to assess neutrophil infiltration.
Results: PCE treatment at all doses significantly reduced ear edema compared to the TPA control.
The PCE response was dose-dependent and 2.5 mg PCE significantly inhibited all markers of
inflammation to a greater extent than indomethacin (0.5 mg). MPO activity was inhibited at PCE
doses ≥ 1.25 mg/ear. Trans-resveratrol inhibited inflammation at comparable doses.
Conclusion: PCE inhibits development of edema and neutrophil infiltration in the TPA-treated
mouse ear model of topical inflammation.
Background
Polygonum cuspidatum Sieb et Zucc., commonly called Jap-
anese knotweed or Mexican bamboo, is a member of the
Polygonaceae family that is widely distributed in Asia and
North America. Interest in Polygonum cuspidatum (PC) has
increased owing to the high concentration of resveratrol
and its glycosides in the root [1,2]. In traditional Chinese
medicine, PC is called Hu Zhang and is used as an analge-
sic, antipyretic, diuretic, and an expectorant. Traditional
uses include treatments for arthralgia, chronic bronchitis,
jaundice, amenorrhea, and high blood pressure [3]. Sev-
eral studies have evaluated the antioxidant capacity of
Polygonum cuspidatum extract (PCE) [4,5], and anti-inflam-
matory activities such as inhibition of NF-kB have been
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reported [6-8]. At present, studies of PCE effects on classic
symptoms of inflammation such as edema and neu-
trophil infiltration are lacking.
PCE is used as an ingredient in many nutraceutical prod-
uct formulations because of its high concentration of
trans-resveratrol, a polyphenolic trans-stilbene (3, 4'-5-tri-
hydroxystilbene). Resveratrol and related phytochemicals
produce antioxidant, cardioprotective, immunomodula-
tory, chemopreventive, anti-bacterial, anti-fungal, and
anti-viral effects [9-14]. The concentration of resveratrol
in sources such as grapes and red wine varies depending
on environmental conditions [15]. Therefore, PCE is
being used commercially as an additive to standardize res-
veratrol concentration in extracts of grape pomace (skins
and seeds) that have low or variable natural concentra-
tions [16,17]. Also, additive and synergistic effects have
been noted for combinations of resveratrol and flavo-
noids such as quercetin and ellagic acid [18].
PCE has not been tested in the tetradecanoylphorbol ace-
tate (TPA)-treated mouse ear model of inflammation. This
model evaluates whether pharmaceutical agents or natu-
ral products may block the inflammatory response to top-
ical TPA [19-21]. Because PCE is being used as an
ingredient in cosmeceutical products that are applied to
the skin and in nutraceutical products that are ingested, it
is worthwhile to test PCE activity in this model. The skin
and gastrointestinal mucosa are both subject to inflam-
mation, but it is far easier to screen for anti-inflammatory
effects on an accessible surface than on an internal epithe-
lium. Therefore, the present study tested whether PCE has
topical anti-inflammatory activities in the well-character-
ized TPA-induced mouse ear model of inflammation,
edema, and PMN leukocyte infiltration [22,23]. Total
phenolics and ferric reducing antioxidant power (FRAP
values) were measured in the ethanolic PCE because both
characteristics may reflect the degree of anti-inflammatory
activity of the preparation. For example, Chung et. al.
reported that edema formation in the TPA model may be
regulated by H2O2 generation [24], as evidenced by anti-
inflammatory activity of several antioxidant compounds
[25,26].
Materials and methods
Materials
12-O-Tetradecanoylphorbol 13-acetate, hexadecyltri-
methylammonium bromide, indomethacin (minimum
99% TLC), 3,3',5,5'-tetramethylbenzidine dihydrochlo-
ride, N, N-dimethylformamide, trans-3,4',5-trihydroxys-
tilbene (trans-resveratrol), Folin-Ciocalteu reagent, gallic
acid, and 10 mM 2,4,6-tripyridyl]-1,3,5-triazine (TPTZ)
were all purchased from Sigma-Aldrich Chemical Co. (St.
Louis, MO). Polygonum cuspidatum 200:1 powdered extract
was purchased from Supplemental Health Formulations
(Mayer, AZ).
Preparation of ethanolic solution of Polygonum 
cuspidatum extract (PCE)
PCE used in this study was a 200-fold concentrate pre-
pared from PC root grown in China. Chemical analysis
from Supplemental Health Formulations reported that
the trans-resveratrol complex was at least 500 mg/g and
emodin content was < 20 mg/g. The 200:1 PC powder was
dissolved in 50% ethanol (1 part PC to 9 parts ethanol)
and stirred for 1 h at 23°C. The mixture was centrifuged
(1500 rpm for 10 min, 4°C) and the supernatant was
diluted for topical dose-response applications in this
study. The majority of the powder was not soluble in 50%
ethanol under these conditions.
Chromatographic analysis of the Polygonum cuspidatum 
ethanolic solution
The ethanolic extract was diluted 400-fold and subjected
to HPLC analysis using an ESA (Chelmsford, MA) system
consisting of a Model 582 Solvent Delivery Module, a
Model 542 autosampler maintained at 6°C and a Model
5600A CoulArray detector at 250 mV. The column was an
MCM C18 (4.6 × 150 mm, 5–120 A) from MC Medical,
Japan. Mobile phase A was 75 mM citric acid, 25 mM
ammonium acetate and 10% acetonitrile; Mobile phase B
was similar to A but with 50% acetonitrile. The gradient
was linear from 0–17 minutes from 10%A to 80%B. Flow
rate was 1.0 ml/min and 20 µl of sample was injected. Res-
veratrol eluted between 16.2 and 16.8 minutes as judged
by a standard obtained from Sigma-Aldrich (St. Louis,
MO).
Measurement of total phenolic compounds
Total phenolic acid content of each extract was measured
by the method of Slinkard and Singleton [27] with minor
modifications. Triplicate samples of a 1:10 extract (wt/
vol) (20 µL) were added to 1.58 mL of distilled water in 3
mL polystyrene cuvettes. 100 µL of Folin-Ciocalteu rea-
gent was added and the sample was mixed well. Within 10
minutes, 300 µL of sodium carbonate solution (200 g
Na2CO3 in 1 L distilled water) was added. Solutions were
incubated for 2 h at room temperature. Absorbance was
measured at 765 nm. Total phenolic acid concentration
was calculated from a gallic acid standard curve (0–500
mg/L) and expressed as gallic acid equivalents per gram
200:1 PCE powder.
Measurement of FRAP values (Ferric Reducing Antioxidant 
Power)
The antioxidant activity of a 1:10 (wt/vol) extraction was
determined in triplicate by the FRAP method [28]. 10 µL
of the sample or standard, 30 µL of distilled water and 300
µL of FRAP reagent were mixed. FRAP reagent was madeJournal of Inflammation 2008, 5:1 http://www.journal-inflammation.com/content/5/1/1
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by mixing 25 mL acetate buffer (300 mM, pH 3.6), 2.5 mL
of 10 mM TPTZ solution dissolved in 40 mM HCl, and 2.5
mL of 20 mM ferric chloride solution. The solutions were
incubated at 37°C for six minutes then 340 µL of distilled
water was added. The absorbance of the sample or stand-
ards was read immediately at 593 nm. FRAP value was cal-
culated from a standard curve of ferrous sulfate (0–1
mmol/L) and the antioxidant power of the PCE was
expressed as mmol ferrous sulfate equivalents/100 g dry
weight of the 200:1 PCE powder.
Animals
All animal experiments were approved by the Institu-
tional Animal Care and Use Committee (IACUC) at the
University of Georgia and conducted according to IACUC
guidelines. The sample size of 8 animals for each test
group was justified on the basis of a pilot experiment
showing that the sample standard deviation (s) for meas-
urements of ear edema was about 5% of the measured
value and the average expected difference (d) between
TPA treated ears and PCE-treated ears was about 0.2 mm.
Assuming that α = 0.05 and 1 - β = 0.9, the formula used
was n (sample size) = 1 + 21*(s/d)2 [29]. The formula gave
6.25, which was increased to 8 in case of unexpected
experimental problems. Female Swiss Webster mice (Har-
lan Laboratories, Indianapolis, IN) weighing 22–25 g
were housed in groups of 4 in large shoebox cages. All
groups were fed a standard rodent diet (TestDiet® 570B,
Purina Mills, St. Louis, MO) ad libitum with free access to
water. Animals were in the fed condition throughout the
experiment. Photoperiods equaled 12 h of light and 12 h
of darkness daily, with the environmental temperature
maintained at 21°C.
TPA-induced mouse ear edema
Edema was induced in both ears of each mouse by the
topical application of 2 µg TPA dissolved in 20 µL of ace-
tone to both the inner and outer ear surfaces. Thirty min-
utes after the application of TPA, the inner and outer
surface of each ear was treated (10 µL to each side) with
50% ethanolic solutions of PCE in doses of 0.075, 0.15,
0.3, 1.25 and 2.5 mg PCE/ear (n = 8 at each dosage). Com-
parisons included equal volumes of 50% ethanol (vehicle
control), indomethacin (0.5 mg/ear dissolved in 50% eth-
anol as an anti-inflammatory drug standard), or a 50%
ethanol solution of trans-3, 5, 4'-trihydroxystilbene (res-
veratrol, 0.6 mg/ear). The thickness of each ear was meas-
ured using a micrometer (Mitutoyo Series IP65, Mitutoyo
America, Aurora, IL) before and at 4 h and 24 h after TPA
administration. The micrometer was applied near the top
of the ear distal to the cartilaginous ridges. At 24 h each
animal was sacrificed with CO2 inhalation by the IACUC
approved protocol. Ear punch biopsies (6 mm diameter
hole punch) were taken immediately, weighed, frozen
and stored at -80°C. A single investigator performed all
ear measurements and biopsies in order to standardize
the procedure and reduce experimental error.
Myeloperoxidase assay
Tissue MPO (MPO, E.C. 1.11.1.7) activity was measured
in biopsies taken from both ears 24 h after TPA adminis-
tration using a method by Suzuki et. al. [30] and modified
by De Young et. al. [31]. Each mouse ear biopsy was
placed in 0.75 mL of 80 mM phosphate-buffered saline
(PBS) pH 5.4 containing 0.5% hexadecyltrimethyl-
ammonium bromide (HTAB). Each sample was homoge-
nized for 45 s at 4°C with a small sample laboratory Tis-
sue Tearor Homogenizer Model 985-370 (Biospec
Products, Bartlesville, OK). The homogenate was trans-
ferred quantitatively to a microcentrifuge tube with an
additional 0.75 mL HTAB in PBS. The 1.5 mL sample was
centrifuged at 12,000 × g for 15 min, maintained at 4°C.
Triplicate 30 µL samples of the resulting supernatant were
added to 96-well microtiter plate wells. For the MPO
assay, 200 µL of a mixture containing 100 µL of 80 mM
PBS (pH 5.4), 85 µL of 0.22 M PBS (pH 5.4), and 15 µL of
0.017% hydrogen peroxide were added to each well. 20
µL of 18.4 mM tetramethylbenzidine HCl in 8% aqueous
dimethylformamide was added to start the reaction.
Microtiter plates were incubated at 37°C for 3 min, and
then placed on ice. The reaction was stopped with the
addition of 30 µL of 1.46 M sodium acetate, pH 3.0. MPO
enzyme activity was assessed colorimetrically using a
BioTek Microplate Reader (Winooski, VT) at an absorb-
ance wavelength of 630 nm. MPO activity was expressed
as optical density (OD)/biopsy.
Statistical analysis
Data are expressed as the mean ± standard error of the
mean (SEM). Statistical evaluations used t-tests and one-
way analysis of variance (ANOVA) with post-hoc tests for
significance of differences by the Student-Newman-Keuls
Method. Statistical significance was considered at p <
0.05.
Results
Total phenolics and FRAP values in PCE
A 50% ethanolic extract (1:10 wt/vol) of the 200:1 PCE
yielded 188 mg of total phenolics (gallic acid equivalents)
per gram of PCE. Antioxidant power based on the FRAP
assay was 85 mmol ferrous sulfate equivalents/100 g dry
weight of PCE. Most of the solids in the commercial
extract were not soluble in 50% ethanol. The dry weight of
the ethanol-insoluble pellet remaining after centrifuga-
tion of the extract from 1.0 g of powder equaled 0.76 g,
indicating that the majority was not soluble in 50% etha-
nol. Chromatography of the ethanol-soluble material as
described in the Methods section showed only one major
peak, which co-eluted with authentic trans-resveratrol
(Figure 1).Journal of Inflammation 2008, 5:1 http://www.journal-inflammation.com/content/5/1/1
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Ear edema
Ear edema was observed in all TPA-treated animals by 4 h
and 24 h after treatment. In animals treated only with
vehicle (50% ethanol), initial ear thickness equaled 0.27
± 0.01 mm (mean ± SEM). Ear thickness increased to 0.42
± 0.01 mm at 4 h and 0.46 ± 0.02 mm by 24 h after TPA
treatment. PCE-treated experimental groups showed sig-
nificantly reduced ear edema compared to TPA treatment
alone. Dosages tested included 0.075, 0.15, 0.3, 1.25 and
2.5 mg PCE/ear (n = 8 at each dosage). PCE at 2.5, 1.25,
and 0.3 mg per ear was as effective as indomethacin (0.5
mg/ear) in reducing edema (Figure 2). These treatments
inhibited edema 61%, 55%, 52%, and 65% (Indo),
respectively compared to TPA treated with vehicle con-
trols. In comparison, 0.62 mg of commercially purified
trans-resveratrol inhibited edema by only 35%. At 24 h, all
experimental groups had significantly reduced ear edema
compared to TPA alone except PCE at 0.075 mg per ear
and the trans-resveratrol-treated groups. PCE at 1.25, 0.3,
and 0.15 mg per ear inhibited edema as well as indometh-
acin (58%, 36%, 40%, respectively, vs 45% for indometh-
acin. PCE applied at 2.5 mg per ear was significantly more
effective than indomethacin in reducing edema with a
73% reduction compared to the TPA treated vehicle con-
trol.
Edema was also indicated by changes in ear punch masses
at 24 h, and the treatment effects were similar to the
changes in ear thickness shown in Figure 2. Typical masses
of ear punch biopsies at 24 h were 9.1 ± 0.3 mg in vehicle-
treated controls compared to 17.5 ± 0.7 mg in TPA-treated
animals. Ear punch biopsy weights were significantly
lower in all PCE groups compared to the TPA-treated con-
trol group (data not shown). For example, 2.5 mg of PCE
reduced the change in ear mass to 1.3 ± 0.25 mg (an 80%
reduction), which was significantly greater than the reduc-
tion by 0.5 mg of indomethacin to 5.36 ± 0.39 mg (36%
reduction). Resveratrol (0.62 mg) produced an effect sim-
ilar to indomethacin, and reduced the change in ear thick-
ness to 6.02 ± 0.38 mg.
Myeloperoxidase activity
Myeloperoxidase activity was measured in the ear punch
biopsies taken 24 h after TPA administration as an index
of neutrophil infiltration (Figure 3). Biopsies from ears
treated with indomethacin at 0.5 mg/ear and PCE at 1.25
and 2.5 mg/ear doses had significantly reduced MPO
activity. The higher PCE dose (2.5 mg/ear) decreased
MPO to 18% of the activity of the TPA-treated vehicle con-
trol group and was significantly more effective at decreas-
ing MPO activity than indomethacin. Indomethacin (0.5
mg/ear) and PCE (1.25 mg/ear) inhibited MPO to the
same extent at 53% and 45%, respectively.
Discussion
An early hallmark of skin irritation and local inflamma-
tion in the TPA model is thickening within 1–4 h due to
increased vascular permeability, edema and swelling
within the dermis [32]. Topical application of PCE signif-
icantly inhibited ear edema at 4 h and 24 h after TPA treat-
ment. Secondarily, PMN leukocytes migrate to the dermis
within about 24 h and may be estimated by the MPO
assay. Both of these inflammatory processes were blocked
by topical application of PCE in a dose-dependent man-
ner. PCE at a dose of 2.5 mg/ear reduced edema and
inhibited leukocyte infiltration to a greater extent than
indomethacin (0.5 mg/ear). Indomethacin is a potent
Change in ear thickness 4 and 24 h after TPA application Figure 2
Change in ear thickness 4 and 24 h after TPA applica-
tion. Ear thickness was measured with a digital micrometer 4 
and 24 h after application of 2 µg TPA. Abbreviations include 
Indo (indomethacin), PCE (Polygonum cuspidatum extract), 
and RV (resveratrol). Results represent means ± SEM. *p ≤ 
0.05 compared to no TPA, **p ≤ 0.05 compared to TPA con-
trol, ***p ≤ 0.05 compared to indomethacin (Indo).
Chromatogram of ethanol-soluble PCE fraction Figure 1
Chromatogram of ethanol-soluble PCE fraction. A 
single major peak was observed in the chromatogram of the 
50% ethanol soluble fraction of PCE that eluted at 16.3 min 
with the same retention time as authentic trans-resveratrol 
(not shown).Journal of Inflammation 2008, 5:1 http://www.journal-inflammation.com/content/5/1/1
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non-steroidal, anti-inflammatory drug. It has an LD50 of
50 mg/kg in mice based on a 14 day mortality response
[33]. This LD50translates to 1.25 mg indomethacin per 25
g mouse, just above the dose administered topically (1
mg/mouse). In contrast, no significant toxicity has been
shown for PCE in this bioequivalence range. These data
show that an ethanolic solution of PCE reduces inflam-
mation to a similar extent as indomethacin or trans-resver-
atrol.
PCE is widely used in nutraceutical products because of
consistently high concentration of resveratrol and its glu-
cosides. Resveratrol derivatives in extracts of PC root
include several glycosides [1,34,35]. In addition, PC con-
tains emodin and a glycoside. However, Figure 1 shows
that the ethanol-soluble fraction of the commercial con-
centrate used here was less complex than crude extracts of
PC root [2,34,35]. The chromatogram agrees with the cer-
tificate of analysis of that PCE powder, 200:1, contains at
least 50% trans-resveratrol and less than 2% emodin. In
our tests, PCE was similar in activity to trans-resveratrol on
a mass basis (Figures 2 and 3).
Our data are consistent with findings that trans-resveratrol
and its derivatives have anti-inflammatory activity. For
example, resveratrol and its glycosides inhibit human
TNF-α and LPS-induced activation of NF-κB [36,37]. Res-
veratrol inhibits induced production of prostaglandin E2
release from human peripheral blood leukocytes [38]. In
a model of early colonic inflammation in rats, resveratrol
significantly decreases elevated plasma levels of prostag-
landin D2 and the expression of COX-2 [39]. Resveratrol
also inhibits the TPA-induced mouse dorsal skin inflam-
matory response by reducing NF-κB and activator protein-
1 [40,41].
The TPA model of ear inflammation is useful for screening
prospective topical anti-inflammatory compounds or
botanical extracts that act at a variety of levels. In epider-
mal cell culture, TPA stimulates cell proliferation and
increases the formation of leukotrienes and prostagland-
ins [42]. Phospholipase A2 inhibitors have proven effec-
tive against both leukocyte infiltration and edema in the
TPA model of ear inflammation [43]. Products of arachi-
donic acid metabolism such as PGI2 and LTB4 increase vas-
cular permeability leading to edema during the
inflammatory response [23], and compounds inhibiting
COX and LOX enzymes have been shown to inhibit TPA-
induced inflammation [23]. TPA applied topically to
mouse ears promotes mast cell infiltration with release of
mediators that increase vascular permeability and pro-
mote neutrophil influx [22].
In addition to 50% resveratrol, PCE extract contains com-
pounds such as quercetin and emodin that have anti-
inflammatory activities. It is known that additive and syn-
gergistic interactions of polyphenols occur in vitro [44,45].
For example, in human leukemia cells, ellagic acid and
quercetin interact synergistically with resveratrol to
induce apotosis and cell cycle arrest [18]. Emodin, an
anthraquinone, is present in PC rhizomes at concentra-
tions similar to resveratrol and piceid [2]. However, the
emodin content in PCE is reduced during processing to
achieve a final content of ≤ 20 mg/g. This is important
because PCE is a constituent in products that are ingested,
and it is desirable to reduce the risk of unpleasant gas-
trointestinal side effects in humans [46]. Emodin is a phy-
toestrogen with anti-viral and anti-inflammatory actions
[47]. It inhibits NF-κB activation and IκB degradation,
and decreases gene expression of cell surface adhesion
proteins in vascular endothelial cells [6]. Emodin also
effectively inhibits gene expression for TNF-α, iNOS, and
IL-10 in RAW 264.7 macrophages by activating IκB [48].
Thus, even though emodin levels in PCE have been
reduced from levels in crude extracts, it may contribute to
the topical anti-inflammatory activity of PCE. The present
work shows that PCE and trans-resveratrol are anti-inflam-
matory in the mouse ear model, and that PCE could pro-
vide anti-inflammatory properties to cosmeceutical and
dermatological products.
Abbreviations used
TPA: 12-O-tetradecanoylphorbol-13-acetate, PMN: Poly-
morphonuclear, MPO: Myeloperoxidase, TNF-α: Tumor
Necrosis Factor – alpha, IL-6, -1β, -8: Interleukin-6, -1β, -
Myeloperoxidase activity Figure 3
Myeloperoxidase activity. Myeloperoxidase activity (an 
index of neutrophil activation) was measured in ear punches 
24 h after TPA administration. Abbreviations include Indo 
(indomethacin), PCE (Polygonum cuspidatum extract), and RV 
(resveratrol). Results represent means ± SEM. *p ≤ 0.05 
compared to no TPA, **p ≤ 0.05 compared to TPA control, 
***p ≤ 0.05 compared to indomethacin.Journal of Inflammation 2008, 5:1 http://www.journal-inflammation.com/content/5/1/1
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8, COX: Cyclooxygenase, LOX: Lipoxygenase, Indo:
Indomethacin, PC: Polygonum cuspidatum, PCE: Polygonum
cuspidatum extract in 50% ethanol
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